- Novo Nordisk agreed to license global rights to HRS-1596, an experimental obesity drug from China's Jiangsu Hengrui Pharmaceuticals, in a deal valued at up to $2.6B.
- Under the agreement Novo Nordisk receives exclusive rights to develop, manufacture, and commercialize the asset.
- The deal adds an external obesity candidate to Novo Nordisk's pipeline as competition in the GLP-1 weight-loss market intensifies.
Quotes
“Jiangsu Hengrui Pharmaceuticals has agreed to license global rights to its experimental obesity drug HRS-1596 to Novo Nordisk (NVO) in a deal worth up to $2.6B.”
“Novo Nordisk (NVO) will receive exclusive rights to develop, manufacture, and commercialize”